-+ 0.00%
-+ 0.00%
-+ 0.00%

Alector halts Phase 2 nivisnebart early Alzheimer’s trial after futility analysis

PUBT·04/29/2026 20:36:30
Listen to the news
Alector halts Phase 2 nivisnebart early Alzheimer’s trial after futility analysis
  • Alector will discontinue Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in early Alzheimer’s disease following interim futility analysis.
  • Independent data monitoring committee concluded study was unlikely to meet primary endpoint, signaling no expected clinical benefit on disease progression.
  • Full trial results were not presented yet; Alector plans to share them at a future medical meeting or congress.
  • Focus shifts to wholly owned ABC-enabled pipeline, including anti-amyloid beta antibody AL037/AL137 with IND submission targeted for Q1 2027.
  • Development work continues on ABC-enabled tau siRNA AL064/AL164, alongside other programs advancing toward lead selection or IND timing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604291605PRIMZONEFULLFEED9709883) on April 29, 2026, and is solely responsible for the information contained therein.